Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 4/2017

01-12-2017 | Drug-Induced Liver Injury (F Bessone and R Andrade, Section Editors)

Hepatotoxicity of New Antitumor Agents

Author: Nelia Hernandez

Published in: Current Hepatology Reports | Issue 4/2017

Login to get access

Abstract

Purpose of Review

Cancer therapy had a noteworthy development in recent years, mostly focused in targeted therapies. Even if it is expected that these agents would be less harmful, their use has been associated with several side effects. This review focuses on hepatotoxicity concerning molecular targeted therapy particularly the tyrosine kinase inhibitors, monoclonal antibodies, and immune checkpoint inhibitors.

Recent Findings

The tyrosine kinase inhibitor hepatotoxicity is one of the serious class-related adverse events and has been linked to severe and fatal liver injury. The use of immune checkpoint inhibitors is associated with autoimmune-like side effects. The mechanism of liver injury is likely to be immunologically mediated, even if serum autoantibodies are not usually present, and responsiveness to corticosteroid therapy is reported.

Summary

New antitumor agents, mainly tyrosine kinase inhibitors and immune checkpoint inhibitors, are a significant cause of liver injury. Even if in most instances, molecular targeted therapy-induced hepatotoxicity is reversible, several of these agents have been linked to fatal liver injury.
Literature
1.
• Ulcickas Yood UM, Bortolini M, Casso D, Beck Jean G, Oliveria SA, Wells K, et al. Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system. Pharmacoepidemiol Drug Saf. 2015;24:426–33. Using automated data, among 2788 chemotherapy-exposed patients, 3.3% had elevated LLTs suggestive of DILI. However, after a medical record review only two patients (0.07%) with chemotherapy have not another potential alternative cause of liver injury
2.
• Chalasani N, Bonkovsky HL, Fontana RJ, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148:1340–52. Last update of cases of drug induced liver injury in the US, collected from 2004. CrossRefPubMedPubMedCentral
3.
Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19.CrossRefPubMed
4.
Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002;8:3034–8.PubMed
5.
Van Hootegem A, Verslype C, Van Seenbergen W. Sorafenib-induced liver failure: a case report and review of the literature. Case Rep Hepatol. 2011;2011:941395.
6.
7.
Klempner SJ, Choueiri TK, Yee E, Doyle LA, Schuppan D, Atkins MB. Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients. J Clin Oncol. 2012;30:e264–8.CrossRefPubMed
8.
Takeda M, Okamoto I, Fukuoka M, Nakagawa K. Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. J Clin Oncol. 2010;28:e273–4.CrossRefPubMed
9.
Peroukides S, Makatsoris T, Koutras A, Tsamandas A, Onyenadum A, Labropoulou-Karatza C, et al. Lapatinib-induced hepatitis: a case report. World J Gastroenterol. 2011;17:2349–52.CrossRefPubMedPubMedCentral
10.
Kapadia S, Hapani S, Choueiri TK, Wu S. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol. 2013;52:1202–12.CrossRefPubMed
11.
• Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 2013;36:491–503. Systematic review of the currently available information on the liver injury potential of tyrosine kinase inhibitors [crizotinib, imatinib, lapatinib, pazopanib, ponatinib, regorafenib, sunitinib]. CrossRefPubMed
12.
• Iacovelli R, Palazzo A, Procopio G, Santoni M, Trenta P, De Benedetto A, et al. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol. 2014;77:929–38. Meta analysis for phase III randomized trials with axitinib, pazopanib, sorafenib, sunitinib, regorafenib or vandetanib. A significant increase in the relative risk of grade 3–4 ALT increase was present for sorafenib and pazopanib but not for sunitinib
13.
Teo YL, Ho HK, Chan A. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treat Rev. 2013;39:199–206.
14.
• Teo YL, Ho HK, Chan A. Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review. Expert Opin Drug Metab Toxicol. 2015;11:231–42. Review of the literature of mechanism of action involved in tyrosine kinase inhibitor-induce hepatotocitiy and the strategies adopted to overcome this adverse event. The experts highlight the formation of reactive metabolites and its potential for liver toxicity
15.
Aliberti S, Grignani G, Allione P, Fizzotti M, Galatola G, Pisacane A, et al. An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient. Am J Clin Oncol. 2009;32:640–1.CrossRefPubMed
16.
Bonvin A, Mesnil A, Nicolini FE, Cotte L, Michallet M, Descortes J, et al. Dasatinib-induced acute hepatitis. Leuk Lymphoma. 2008;49:1630–2.CrossRefPubMed
17.
• Spraggs CF, Parham LR, Briley LP, Warren L, Williams LS, Fraser DJ, et al. Characterization of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes. Pharmacogenomics J. 2017; https://​doi.​org/​10.​1038/​tpj.​2017.​39. Among 8381 patients with HER2- overexpressing primary breast cancer treated with lapatinib or trastuzumab or both, HLADRB1* 07:01 carriage was associated with serum ALT elevations in lapatinib-treated patients. The authors suggest that the use of genetic testing may support causality discrimination and safety risk management during the use of this therapy
18.
Xu CF, Reck BH, Goodman VL, Xue Z, Huang L, Barnes MR, et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol. 2011;54:1237–43.CrossRefPubMed
19.
• Spraggs CF, Xu CF, Hunt CM. Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. Pharmacogenomics. 2013;14:541–54. Review of genetic studies of lapatinib and pazopanib demonstrating different mechanisms of hepatotoxicity and the utility of genetic studies to improve safety management. CrossRefPubMed
20.
Westgeest HM, van Erp NP, Honeywell RJ, Hoekstra R, Peters GJ, Verheul HM. Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure. J Clin Oncol. 2013;31:e83–6.CrossRefPubMed
21.
Klinger M1, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. 2009;35:515–20.CrossRefPubMed
22.
Muñoz A, Carrera S, Ferreiro J, Ruiz de Lobera A, Mañe JM, Lopez-Vivanco G. Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer. Ann Oncol. 2007;18:2045–6.CrossRefPubMed
23.
24.
Srinivasan S, Parsa V, Liu CY, Fontana JA. Trastuzumab-induced hepatotoxicity. Ann Pharmacother. 2008;42:1497–501.CrossRefPubMed
25.
• Sadeghi S, Olevsky O, Hurvitz AS. Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. Pharmagenomics Pers Med. 2014;15:329–38. Review of data relating to trastuzumab emtansine use for (HER2)-positive breast cancer. The most common toxicities described were thrombocytopenia and an elevation in liver transaminases
26.
• Force J, Saxena R, Schneider BP, Storniolo AM, Sledge GW Jr, Chalasani N, et al. Nodular regenerative hyperplasia after treatment with trastuzumab emtansine. J Clin Oncol. 2016;20:34:e9–12. Two women presented with ascites, varices, and low platelet 16 months after starting therapy with trastuzumab emtansine for metastatic breast cancer. Liver biopsy demonstrated nodular regenerative hyperplasia. Both patients were improving after the drug was interrupted.
27.
• Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One. 2016;11(7):e0160221. https://​doi.​org/​10.​1371/​journal.​pone.​0160221. Systematic review of case reports describing immune-related adverse events in patients receiving ipilimumab, nivolumab, or pembroluzimab. Among 251 cases, the majority treated with ipilimumab (93.2%), autoimmune colitis, hepatitis, endocrinopathies, and cutaneous irAEs were the most frequently reported adverse event. Gastrointestinal adverse events were not reported in patients treated with pembrolizumab [10 cases] or nivolumab [7 cases]. CrossRefPubMedPubMedCentral
28.
29.
• Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol. 2015;39:1075–84. Clinical and histological features of 11 patients with liver injury after 1 to 4 doses of ipilimumab; 10 men, median age 58 y. Nine biopsies showed active hepatitis with prominent sinusoidal histiocytic infiltrates and central vein damage with endothelialitis (8 cases). Discontinuation of ipilimumab and immunosuppressive therapy resulted in resolution or marked improvement of LFTs in all patients within 3 months of presentation
30.
• Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691–7. Review of the immune-related adverse events associated with ipilimumab and their management. The authors recommend use of high doses of corticosteroids for 2 days followed by tapering doses to at least 30 days, and ipilimumab should not be restarted. CrossRefPubMed
31.
• Imafuku K, Yoshino K, Yamaguchi K, Tsuobi S, Ohara K, Hata H. Successful treatment of sudden hepatitis induced by long-term nivolumab administration. Case Rep Oncol. 2017;10:368–71. 57 year old man with metastatic melanoma developed asymptomatic hepatitis after 34 weeks of nivolumab. The AST/ALT level improved after the patient stopped taking nivolumab and was treated with 1.0 mg/kg/day of systemic cortico
32.
• Simonelli M, Di Tommaso L, Baretti M, Santoro A. Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. Immunotherapy. 2016;8:1363–9. 68 years old man with glioblastoma developed colitis and hepatitis after 4 courses of nivolumab. The patient had promptly responsiveness to corticosteroid therapy and to suspension of nivolumab therapy but recurred after the tapering of corticosteroids. CrossRefPubMed
Metadata
Title
Hepatotoxicity of New Antitumor Agents
Author
Nelia Hernandez
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 4/2017
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-017-0381-7

Other articles of this Issue 4/2017

Current Hepatology Reports 4/2017 Go to the issue

Fatty Liver Disease (S Harrison and J George, Section Editors)

Wet Biomarker-Based Assessment of Steatosis, Inflammation, and Fibrosis in NAFLD

Drug-Induced Liver Injury (F Bessone and R Andrade, Section Editors)

Biochemical and Molecular Mechanisms of Liver Damage-Induced by Antidepressant Drugs: an Update Review

Fatty Liver Disease (S Harrison and J George, Section Editors)

Role of Exercise in NAFLD/NASH: What is the Right Prescription?

Fatty Liver Disease (S Harrison and J George, Section Editors)

Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C

Fatty Liver Disease (S Harrison and J George, Section Editors)

Managing the Burden of Non-NASH NAFLD

Drug-Induced Liver Injury (F Bessone and R Andrade, Section Editors)

Autoimmune Hepatitis-Induced by Drugs: a Challenging Diagnosis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits